Pulmonary arterial hypertension: Classification, diagnosis and contemporary management

Postgraduate Medical Journal

Volumn 82, Issue 973, 2006, Pages 717-722

  Fox, D J ^a   Khattar, R S ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ENDOTHELIN RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN;

DRUG ANTAGONISM; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HUMAN; METHODOLOGY; PULMONARY HYPERTENSION; REVIEW;

ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE INHIBITORS; RECEPTORS, ENDOTHELIN;

EID: 39049176894     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2006.044941     Document Type: Review

References (39)

1. Rubin LJ. Executive summary: diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:4S-6S.
2. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:S5-12.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1999;353:74-6.
4. Farber HW, Loscalzo J. Mechanisms of disease. N Engl J Med 2004;351:1655-65.
5. Currie PJ, Seward JB, Chan KL, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 1985;6:750-6.
6. Fishman AJ, Moser KM, Fedullo PF. Perfusion lung scans versus pulmonary angiography in evaluation of suspected primary pulmonary hypertension. Chest 1983;84:679-83.
7. Murata I, Kihara H, Shinohara S, et al. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J1992;56:983- 91.
8. de Chadarevian JP, Lischner HW, Karmazin N, et al. Pulmonary hypertension and HIV infection: new observations and review of the syndrome. Mod Pathol 1994;7:685-9.
9. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The international PPH consortium. Nat Genet 2000;26:81-4.
10. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
11. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. New Engl J Med 1992;327:76-81.
12. Wang SWS, Pohl JEF, Rowlands DJ, et al. Diazoxide in treatment of primary pulmonary hypertension. Br Heart J 1978;40:572-4.
13. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151 :384-9.
14. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-7.
15. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
16. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomised controlled trial. Ann Intern Med 2000;132:425-34.
17. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
18. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
19. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil:an epoprostenol analogue for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-9.
20. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue, iloprost, in man. Eur J Clin Pharmacol 1986;30:61-8.
21. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
22. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
23. Kim H, Yung GL, Marsh JJ, et al. Endothelin mediates pulmonary vascular remodeling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J 2000;15:640-8.
24. Maclean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther 1998;11 :125-32.
25. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endotheli-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
26. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo controlled study. Lancet 2001;358:1119-23.
27. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;30:2489-92.
28. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin receptor antagonist, in patients with pulmonary arterial hypertension:open label pilot study. Chest 2002;121:1860- 8.
29. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7.
30. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-a selective antagonist. J Med Chem 1997;40:1690-7.
31. Braner DA, Fineman JR, Chang R, et al. M&B 22948, A cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993;264:H252-8.
32. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993;74:1704-11.
33. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in paediatric patients with pulmonary hypetension. Am J Respir Crit Care Med 1998;158:1388-95.
34. Sastry BK, Narasimhan C, Reddy NK, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 2002;54:410-4.
35. Stiebellehner L, Petkov V, et al. Long term treatment with oral Sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123:1293-5.
36. Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:63S- 71S.
37. Kerstein D, Levy P, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995;91 :2028-35.
38. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilatation atrial septostomy in severe primary pulmonary hypertension; a therapeutic alternative for patients non responsive to vasodilator treatment. J Am Coll Cardiol 1998;32:297-304.
39. ASTP, ATS, ERS, ISHLT joint statement. International guidelines for the selection of lung transplant patients. Am J Respir Crit Care Med 1998;158:335-9.